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Abstract
Background: GISTs are a subset of mesenchymal tumors and represent the most common
mesenchymal neoplasms of GI tract. However, GIST is a recently recognized tumor entity and the
literature on these stromal tumors has rapidly expanded.
Methods: An extensive review of the literature was carried out in both online medical journals
and through Athens University Medical library. An extensive literature search for papers published
up to 2009 was performed, using as key words, GIST, Cajal's cells, treatment, Imatinib, KIT, review
of each study were conducted, and data were abstracted.
Results: GIST has recently been suggested that is originated from the multipotential mesenchymal
stem cells. It is estimated that the incidence of GIST is approximately 10-20 per million people, per
year.
Conclusion: The clinical presentation of GIST is variable but the most usual symptoms include the
presence of a mass or bleeding. Surgical resection of the local disease is the mainstay therapy.
However, therapeutic agents, such as Imatinib have now been approved for the treatment of
advanced GISTs and others, such as everolimus, rapamycin, heat shock protein 90 and IGF are in
trial stage demonstrate promising results for the management of GISTs.
Background
GISTs (Gastrointestinal tumors) are a subset of mesenchy-
mal tumors and represent the most common mesenchy-
mal neoplasms of GI (Gastrointestinal) tract.
Gastrointestinal stromal tumors are KIT-expressing and
KIT (tyrosine kinase receptor - CD117)-signaling driven
mesenchymal tumors. Many GIST tumors have an activat-
ing mutation in either KIT or PDGFR (Platelet-Derived
Growth Factor Receptor Alpha) [1]. They account for <1%
of all GI tumors. Their origin was at first attributed to
Cajal's cells, in mesodermal tissue but it has nowadays
been recognized that GISTs arise from multipotential
mesenchymal stem cells [2]. However, GIST is a newly rec-
ognized tumor entity but the literature on these stromal
tumors has swiftly expanded. In the past, these tumors
were presumed to have elements of smooth muscle
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(smooth muscle origin), so they were classified as leiomy-
omas, leiomyosarcomas and leiomyoblastomas [3]. The
term was first coined by Mazur and Clark, in 1983, in
order to describe a heterogeneous group of gastrointesti-
nal non-epithelial neoplasms. In 1998, Hirota reported
that GISTs contained activating c-kit mutations, which
play a central role in its pathogenesis [4]. Furthermore,
GISTs express CD34 (cluster designation 34) and the KIT
on their surface [5]. The origin of these tumors explicates
their resistance to cancer chemotherapy. Moreover, it was
their origin that lead to the introduction of a chemother-
apeutic regimen, imatinib mesylate, a tyrosine kinase
inhibitor for c-kit. GISTs are, finally, defined as pleomor-
phic mesenchymal tumors of the GI tract that express the
KIT protein (CD 117- Protooncogene that encodes the
transmembrane tyrosine kinase receptor CD 117 detected
by flow cytometry in most cases of acute myeloid leuke-
mia, in small numbers of T- and B-lymphoblastic lym-
phomas, and in some gastrointestinal stromal tumors -
stem cell factor receptor) and often also CD34 (human
progenitor cell antigen) on immunohistochemistry [6].
Epidemiology
The incidence of GIST is estimated to be approximately
10-20 per million people, per year. Malignancy possibility
is 20-30% [7-9]. However, the precise incidence of GIST is
unknown because of the incomplete definition and classi-
fication [10]. Over 90% of GISTs occur in adults over 40
years old, in a median age of 63 years. However, GIST
cases have been reported in all ages, including children.
The incidence between the sexes is the same, although a
study reported that there is a slight predominance of
males [7]. There are no elements that indicate any associ-
ation with geographic location, ethnicity, race or occupa-
tion. The most common location of GIST is stomach (50-
60%) and small intestine (30%-40%). Five to ten percent
of GISTs arise from the colon and rectum, and 5% are
located in the esophagus. Other less common locations
are those outside of the GI tract, like mesentery, retroper-
itoneum and omentum. However, there have been
reported rare cases in the gallbladder, pancreas, liver and
urinary bladder. In cases, where GIST occurs outside the
GI tract, the tumors are known as extra - gastrointestinal
stromal tumors (EGISTs) [11].
Clinical Presentation
The clinical presentation of GIST is erratic. Furthermore,
only 70% of the patients are symptomatic, while 20% are
asymptomatic and 10% are detected at autopsy [6,7]. The
symptoms and signs are not disease - specific and as a con-
sequence, about 50% of GISTs have already metastases at
the time of diagnosis. The clinical signs and symptoms are
related to the presence of a mass or bleeding [12]. How-
ever, as it is mentioned above, 10% remain asympto-
matic, because of their small size (< 2 cm) and they are
diagnosed incidentally [13]. Bleeding comprises the most
common symptom and it is attributed to the erosion of
the gastrointestinal tract lumen. Bleeding occurring into
the abdominal cavity leads to acute abdominal pain that
usually ends up in emergency surgery. Nevertheless,
bleeding can take place into the GI tract lumen, causing
haematemesis, melena or anemia. Another common find-
ing is the abdominal mass. However, most of the patients
present with vague symptoms, such as nausea, vomiting,
abdominal discomfort, weight loss or early satiety. Rap-
ture of GISTs into the peritoneal cavity is rare and it causes
life threatening intraperitoneal hemorrhage [14]. There
are also symptoms related to the location of GIST. These
symptoms include dysphagia in the esophagus, biliary
obstruction around the ampula of Vater or even intrussus-
ception, in the small bowel. Lymph nodes metastases are
not common in GISTs. On the other hand, distant metas-
tases most commonly occurs in GIST tumors of perito-
neum, omentum, mesenteric areas and liver, while in
EGISTs tumors are rare. At this point, it is important to
mention that rectal GISTs frequently metastasize to the
lung. GISTs have a high tendency to seed. The intra
abdominal lesions result from tumor cell seeding into the
abdominal cavity, whereas liver metastases derive proba-
bly from haematogenous spread. Finally, GIST patients
may present with metastases in surgical scars [15].
Diagnosis
GISTs show a variety of differentiation spectrum, ranging
from fully differentiated tumors with myoid, neural or
ganglionic plexus phenotype to those with incomplete or
mixed differentiation. Nowadays, by the means of immu-
nohistochemistry, it has become clear that the GIST cells
are closely related to the multi-potential mesenchymal
stem cells. In Table 1, differential diagnosis is being eluci-
Table 1: Tumor types in differential diagnosis with GIST
• leiomyoma
leiomyosarcoma (LMS)
• Schwannoma
malignant peripheral nerve sheath tumor (MPNST)
neurofibroma
• neuroendocrine tumor
carcinoid
carcinosarcoma
• fibromatosis or desmoid tumor
solitary fibrous tumor
inflammatory fibroid polyp
• angiosarcoma
clear cell sarcoma
liposarcoma
synovial sarcoma
• malignant mesothelioma
• dedifferentiated carcinoma
sarcomatoid carcinoma
• metastatic melanomaWorld Journal of Surgical Oncology 2009, 7:61 http://www.wjso.com/content/7/1/61
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dated [16]. GISTs are positive for KIT [17]. Generally,
GIST vary greatly in size from a few millimeters to >30 cm,
the median size though is between 5 cm and 8 cm. Mac-
roscopically, GIST usually has an exophytic growth and as
a result, the intra-operative appearance commonly resem-
bles of a mass, that is attached to the stomach, projecting
into the abdominal cavity and displacing all the other
organs [18]. Yet, mucosal ulceration is present in 50%
cases. Additionally, GISTs are smooth gray and white
tumors which are well circumscribed, usually with a
pseudo-capsule. Less frequently, a small area of hemor-
rhage, cystic degeneration and necrosis may be visible
[19]. GISTs have many different histological features. Gas-
tric GISTs have a solid or nested form, often with a hyali-
nized stroma that shows myxoid change. GISTs in the
small intestine, though, are more often spindled than epi-
thelioid and may show a paragangliomatous pattern.
Another characteristic is the eosinophilic structures, com-
posed of collagen, which are stained brightly with PAS
(periodic acid-Schiff stain). Even though, studies on
esophageal, colonic and eGISTs are few, colonic and
anorectal GISTs are more similar to intestinal than gastric
GISTs, while esophageal GISTs resemble to gastric GISTs.
Perinuclear vacuolization is a usual finding in gastric
GISTs and reinforces the relationship between ICCs
(Interstitial cell Cajal) and smooth muscle cells. Con-
versely, GISTs in the small intestine are more often spin-
dled than epithelioid and may show a paragangliomatous
pattern [12]. Diagnosis of GIST is often delayed, due to
the vague nature of symptoms, for even 6 months after the
onset of the symptoms. [10]. Although, the diagnostic
procedure includes several examinations, like barium
examination of the GI tract, computer tomography and
angiography, none of them can establish the diagnosis.
The preoperative percutaneous biopsy should not be used
because it is associated with a significant risk of tumor
rupture or dissemination [20]. The significance of endo-
scopic ultra-sound guided fine needle aspiration has been
pointed out in several studies and the reported accuracy is
80% - 85% [21]. One recent study [22] suggested that EUS
(Endoscopic ultrasound) findings on tumor characteris-
tics, such as size (5 cm), irregular border, extraluminal
growth, and heterogeneity can be used to predict malig-
nant potential of GISTs. At this point, it should be empha-
sized that GISTs always have a malignant potential,
although they may appear benign. One other study [23]
evaluated pre-operative EUS criteria of 35 subepithelial
upper gastrointestinal (UGI) lesions. Twenty six lesions
were leiomyomas and 9 were leiomyosarcomas. This
study was published in 1997, prior to the recognition of
GIST as a distinct pathologic entity. In this study, tumor
size (< 4 cm), irregular extraluminal border, echogenic
foci and cystic spaces independently predicted malignant
lesions. A French study similarly assessed EUS criteria of
56 surgically resected UGI (Upper GastroIntestinal)
lesions and found that irregular extraluminal border,
cystic spaces and malignant appearing lymph nodes were
predictive of malignant or borderline stromal cell tumors
[24]. Although EUS criteria are helpful in identifying
GISTs, which should be resected, the key to pre-opera-
tively determining malignant potential lies in cytology,
histology, and immunohistochemistry. The development
of EUS FNA as well as EUS trucut needle biopsy (TNB) has
clearly improved endosonographers ability to diagnose
GIST, but whether EUS FNA and EUS TNB can help deter-
mine malignant potential of GISTs pre-operatively is still
unclear. Mitotic figures can be determined on EUS TNB
specimens, but TNB specimens may not represent the
entire lesion. There is considerable interest in performing
immunohistochemistry on EUS FNA and EUS TNB speci-
mens in attempt to predict malignant potential. For exam-
ple, an abstract report of 17 patients with resected GISTs
demonstrated that c-kit gene mutational analysis, as well
as staining for MIB-1 were both predictive of malignant
potential [25]. Another study demonstrated that the sen-
sitivity and diagnostic yield of EUS-FNA for the diagnosis
of GIST compare favorably with other well-accepted indi-
cations of this procedure, such as sampling pancreatic
lesions and lymph nodes. More conventional sampling
techniques, such as forceps biopsy or EMR, are limited in
their clinical utility, given the difficulty of sampling
lesions in a subepithelial location and the increased risk
for perforation, respectively. In addition, a clear role for
EUS-guided Tru-cut biopsy has yet to be defined, given
inconsistent results in its ability to provide adequate tis-
sue yield. More studies will have to be performed to fur-
ther elucidate a well-defined role for these alternative
sampling techniques. However, at present, EUS-FNA
should be considered the procedure of choice to secure a
tissue diagnosis of GIST. In examining features of GIST
that are predictive of the ability to obtain adequate tissue
yield, increasing size up to 10 cm, round/oval shape, and
location in a specific sonographic wall layer were statisti-
cally significant in their ability to predict adequate tissue
yield. Duodenal location, size  10 cm, irregular shape,
and unclear sonographic wall layer were significantly
associated with inadequate tissue yield and thus with
non-diagnostic cytology samples. Statistical significance
was demonstrated for each anatomic factor studied, while
none of the biologic or procedural factors were found to
be of significance. These findings demonstrate that EUS-
guided FNA sampling may not necessarily be dependent
on the histological composition of the tumor. There was a
trend toward intermediate/high risk histological findings
in the non-diagnostic group. However, this was likely
because size represents 1 of the 2 criteria used in stratify-
ing the malignant risk for GIST (mitotic count being the
other), as described by Fletcher et al. [12]. The GISTs are
CD117 positive in a percentage of 90% - 95%. Half of
cases show cytoplasmic dot like positivity (Golgi pattern).World Journal of Surgical Oncology 2009, 7:61 http://www.wjso.com/content/7/1/61
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Furthermore, dot like KIT immunoassaying is very sugges-
tive of a c-kit mutation, being present in 71% of c-kit
mutated GISTs [26].
Prognostic Factors
GISTs have an uncertain clinical behavior ranging from
benign to frankly malignant, making the outcome totally
unpredictable. Over the years, many factors have been
examined, such as size, histomorphology, immunohisto-
chemistry and molecular genetics. However, it is difficult
to predict the malignancy potential. Thus, there is not an
accepted staging system for GIST. Multiple parameters
have been considered as predictors of malignancy. At
present, size and mitotic count appear to be the most use-
ful predictors of the malignant behavior [26]. GISTs
always have a malignant potential, even if they appear
benign. Tumors <5 cm are usually low-risk, while those >5
cm are malignant. Even though size <5 cm is reassuring,
we cannot always predict them as benign, as there is
always the chance to metastasize [27]. Furthermore, the
mitotic count is a reliable parameter. Mitoses <5 per 50
high power fields (HPF), usually characterizes GISTs as
benign. Duodenal stromal tumors is characterized as
benign have <2 mitoses per 50 HPF, while the cutoff for
ileal GIST is 5 mitoses per 50 HPF. It is important to point
out that fifty HPF is the minimum number of HPFs neces-
sary to generate an accurate index of proliferative activity
[28]. However, GISTs in stomach, measuring 5-10 cm,
usually, have a good prognosis, as long as the mitotic
count or Ki67 rate is low. On the other hand, small intes-
tine tumors >5 cm behave in an aggressive way, regardless
of the mitotic index. Finally, GISTs occurring anywhere,
that measure >10 cm, tend to behave in a malignant way.
Many studies [26] have indicated that there are several fea-
tures, such as sclerosing that are related to a more favora-
ble prognosis, while a hypercellular sarcomatous
appearance predicts an aggressive behavior. In gastric
tumors, diffuse nuclear atypia, coagulative necrosis and
ulceration have been found to be prognostic unfavorable
features while nuclear palisading and skeinoid fibers were
favorable in a large series by Miettinen et al. [29]. Immu-
nohistochemical markers may be of importance in pre-
dicting the malignant behavior of GISTs. Increased
expression of cell cycle markers (MIB-I or Ki-67) have
been linked to a less favorable prognosis in larger studies
[30]. P16 is a tumor suppressor gene that inhibits cell
cycling by arresting cells in G1 before entry into the S
phase. P16 has been found to be down-regulated in malig-
nant GISTs in some studies [31] but the same down-regu-
lation has been found to be a prognostically favorable
variable in other studies [32]. The National Institute of
Health (NIH) Workshop, in 2001, suggested that a classi-
fication of GISTs in terms of their relative risk of aggressive
behavior, rather than as benign or malignant, seems to be
necessary. The guidelines recommend classifying GISTs
into risk categories, based on size and mitotic count,
emphasizing that no lesion can be definitely labeled as
benign. Until recently, only mitoses and size of tumors
were considered as highly important prognostic factors
when evaluating the risk for metastasis and residual dis-
ease in patients with GISTs. The evaluation was based on
a consensus approach after a GIST workshop by the
National Institute of Health and often called the NIH Risk
Stratification Categories. [12] Gastric tumors were later
found to have a more favorable outcome than tumors
arising from other locations [33] and the guidelines on
risk classification have now been updated by Hornick and
Fletcher [34] which includes location as an additional fac-
tor. Mutations in KIT exon 11 are found to be more com-
mon in larger tumors, and the presence of this mutation
has been shown to have an adverse prognostic influence
[35]. Deletions compared with point mutations in exon
11, have also been found to be a significant unfavorable
factor in patients with gastric GISTs [36].
Management of Gist
Management of localized Gist
Surgical resection of the local disease is the gold standard
therapy. Its goal is complete resection of the disease with
avoidance of tumor rupture [37]. Tumor size determines
the survival and not the negative microscopic surgical
margins [38]. Regional lymph node resection has no value
since GIST rarely gives rise to lymph node metastases.
However, the tumor size or its location may determine the
exact extent of resection [39]. En block resection of the
local disease is recommended when GISTs adheres to con-
tiguous organ. GISTs are soft and fragile, so a tumor rup-
ture must be avoided because it is associated with an
increased risk for development of peritoneal implants
[37]. Complete surgical resection is connected with 48-
65% five year survival [39]. Partial resection must only be
performed in case of large tumors, for palliative purposes
or the control of symptoms or complications, such as
compression of other organs, hemorrhage or even pain
[40]. As it is already mentioned, surgery is the preferred
management of GISTs, where feasible. However, there is
also evidence that laparoscopic approach is effective, with
minimal morbidity and no reported mortality [40]. If a
laparoscopic resection is contemplated, several factors
including patient characteristics, tumor size, location,
invasion as well as the surgeon's experience need to be
taken under consideration [41,42]. The aim of the laparo-
scopic surgery is the same, aiming at the complete
removal of the tumor, avoiding tumor rupture, as perito-
neal seeding affects disease free period [43,44].
Management of advanced GIST (metastatic and recurrent)
Standard treatment for primary gastrointestinal stromal
tumor (GIST) is complete surgical resection, with the aim
to obtain negative microscopic margins over the organ ofWorld Journal of Surgical Oncology 2009, 7:61 http://www.wjso.com/content/7/1/61
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origin [40]. In some cases, because of the anatomic site or
the tumor size, complete resection is either not feasible or
possible only through extensive procedures with expected
major functional morbidity. Imatinib mesylate is a very
active agent for tumor control in advanced and metastatic
GIST [37]. GISTs have a high risk of metastatic relapse.
The usual site of recurrence is the liver (65%), the perito-
neal surface (50%) and both (20%). GIST's response to
conventional chemotherapy is very poor (<10%), while
radiotherapy is only used for analgesic purposes or in
cases of intra peritoneal hemorrhage [26]. GISTs may
show poor response to chemotherapy, but not to imatinib
mesylate, also known as STI571 [11,45] which was found
to act as a powerful selective inhibitor of tyrosine kinases
of PDGFR and of c-kit receptor. Imatinib was initially
designed as a PDGFR inhibitor and its efficacy as a tyro-
sine kinase was assessed in chronic myeloid leukemia
[46]. The use of Imatinib mesylate in recurrent or meta-
static, resectable or not GIST in prospective trial has
shown response in 50% patients, and in approximately
75-85% patients have at least stable disease. The 2-year
survival after Imatinib therapy is approximately 70% and
50% of the patients showed no progression of the disease
[2]. Imatinib interruption after 1 year is associated with a
high risk of relapse, even for patients in complete remis-
sion [47]. The treatment should continue until progres-
sion, intolerance or patient refusal. The treatment is
usually well tolerated, but includes mild to moderate
adverse effects such as edema (usually periorbital) [48],
nausea, muscle cramps, diarrhea, headache, dermatitis,
fatigue, vitiligo [49], hypothyroidism [50], cutaneous pig-
mentation [51] and abdominal pain. In patients with
large bulky tumors, serious adverse events may include
gastrointestinal, intraabdominal hemorrhages [52], cardi-
otoxicity [53] and serosal inflammation [54]. Other
observed effects comprise neutropenia, leukopenia and
abnormal liver function [55]. The ideal dose of Imatinib
is not determined, but the current data show no added
benefit with doses greater than 400 mg/day. All studies
[44] on the dosage of Imatinib suggest that doses of 400-
800 mg/day are safe, efficacious and patients tolerate it
well. Imatinib was approved by the FDA for treatment of
unresectable and metastatic GISTs on 1 February, 2002.
Higher dosage is associated with symptoms of toxicity
[46]. The common side effects of the drug consist of
edema, rash, nausea, diarrhea, myalgia, fatigue, headache,
and abdominal pain [56]. Recent study has confirmed
that stopping of Imatinib is associated with an increased
risk of disease progression but it is not known whether the
discontinuation of Imatinib followed by reintroduction
when the disease progresses is associated with a reduction
in the survival [57]. Even though, Imatinib is a revolution
for the management of GIST, it is not appropriate for all
the cases of GIST. Even if it is rare, resistance to Imatinib
has been reported [2,7,26]. There are patients, who do not
respond to treatment with Imatinib or present an aggrava-
tion within 6 months during such treatment. These
patients have primary resistance and usually have tumors
with KIT exon 9 mutation or a non detectable kinase
mutation [28]. Primary resistance to Imatinib is rare and
affects only 15% of patients [39]. There is, also, another
group of patients who has progression of tumor after at
least 6 months of measurable response to Imatinib [55]
and we used to say that they have a secondary resistance
to Imatinib. Half of the patients, who initially respond,
become resistant by 2 years after Imatinib initiation [57].
The common mechanism of acquired resistance is second-
ary kit mutation. Resistant lesions appear on imaging
studies as a growing nodule in the pre-existing tumor. Pri-
mary and secondary resistance to Imatinib is also becom-
ing a major clinical problem in the treatment of this
disease. Therefore, new drugs that can be served as alter-
native therapies in Imatinib-resistant patients with GIST
or that can be used in combination with Imatinib are
needed [2]. The first clinical studies demonstrate that
Imatinib is the first effective treatment for non resectable
or metastatic GIST [56]. However, long-term results have
not been extracted yet, because of the short time of use. It
is obvious that further clinical studies must be designed
[58-60].
Drugs for GISTs
The use of Imatinib as an adjuvant therapy after complete
primary GIST resection is under evaluation. The American
College of Surgeons Oncology Group (ACOSOG) has
conducted a prospective trial to patients after complete
resection of the tumor [42]. The dose of Imatinib was 400
mg/day for 12 months [26]. The data from this study
showed promising results, since Imatinib [2] is well toler-
ated in the adjuvant setting. However, other trials [2,28],
administering Imatinib and placebo as adjuvant therapy,
showed no difference in the overall survival between the
two groups. At present, the use of Imatinib in an adjuvant
setting should be considered experimental and physicians
should be encouraged to enroll patients in clinical trials.
While tyrosine kinase inhibitors have improved survival
in advanced GISTs, complete response is rare. Further-
more, it is now clear that the majority of patients who ini-
tially benefit from tyrosine kinase inhibitors eventually
become resistant, with a median time to progression on
Imatinib mesylate of 2 years. Responses to Imatinib GIST
patients depend on the presence and genomic location of
KIT mutations [1]. Furthermore, the use of Imatinib neo-
adjuvant therapy with or without an adjuvant treatment
might help in controlling micrometastatic disease, since
GIST tend to spread. The duration and dose of Imatinib in
the neoadjuvant setting are yet undecided, however, less
than 5% patients have complete clinical response to Imat-
inib. In patients who develop focal resistance, with some
tumors progressing on Imatinib and others remaining sta-World Journal of Surgical Oncology 2009, 7:61 http://www.wjso.com/content/7/1/61
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ble [26], surgery can be considered for the progressive dis-
ease component. By resecting clones of disease that have
acquired drug resistance, surgical debulking may prolong
survival in patients with metastatic disease, as long as the
remaining disease remains drug responsive [60]. In con-
clusion, the histological response to Imatinib is varied
and does not correlate well with the clinical response. The
clinical outcome in stable or partial responsive GIST
patients does not seem to be influenced by either the
duration of the Imatinib treatment, the histological
response, or the size of the tumor. Second-site KIT muta-
tions are rare in GISTs response to Imatinib, compared
with Imatinib-resistant tumors, which harbor KIT kinase
domain mutations in half of the cases. Chronic inhibition
of KIT signaling by imatinib may induce tumor cells trans-
differentiation into a smooth muscle phenotype, in a sub-
set of cases, as suggested by the ultrastructural findings
and microarray studies. Lastly, it is speculated that the
presence of p53 gene alterations in GIST does not seem to
affect clinical and histological response to imatinib [1].
The therapeutic effect of several compounds other than
kinase inhibitors have been examined in models of GISTs.
Rossi et al. [61] used knock-in mice with a Kit gain of-
function mutation in the JM domain (Organoplatinum
compound possessing antineoplastic activity) [62]. KIT-
positive and imatinib-sensitive GISTs spontaneously
developed in the knock-in mice. They administered an
inhibitor of mTOR, RAD001 (everolimus), to the knock-
in mice. Mammalian target of rapamycin (mTOR) regu-
lates the translational response by phosphorylating com-
ponents of the protein synthesis machinery. RAD001 did
not induce apoptosis but near-complete arrest of cell-cycle
progression in the imatinib-sensitive GISTs. Since phos-
phorylation of mTOR depends on KIT signaling in the
imatinib-sensitive GISTs, RAD001 did not show any syn-
ergistic effect with imatinib in this setting. In contrast,
RAD001 might be effective in imatinib-resistant GISTs
[61]. Heat shock protein 90 (HSP90) protects KIT from
proteasome-mediated degradation. Bauer et al [63] exam-
ined the effect of an HSP90 inhibitor (17-allylamino-18-
demethoxy-geldanamycin, 17-AAG) on KIT-expressing
and imatinib-sensitive, KIT-expressing but imatinib-resist-
ant and KIT-non-expressing and imatinib-resistant
human GIST cell lines. The proliferation of the KIT-
expressing and imatinib-sensitive and KIT-expressing but
imatinib-resistant cell lines was inhibited by 17-AAG, but
that of the KIT-non-expressing and imatinib-resistant cell
line was not. These results indicated that the expression of
KIT is essential for the therapeutic effect of 17-AAG. Fla-
vopiridol is a transcriptional repressor of numerous genes,
including Kit. Sambol et al. 97 examined the effect of fl
avopiridol on a KIT-expressing but imatinib resistant
human GIST cell line. The flavopiridol treatment caused
apoptosis of the target cells. These three compounds,
RAD001, 17-AAG and flavopiridol, or their derivatives
might be useful for treatment of imatinib-resistant GISTs.
IGF1R is amplified and over-expressed in the majority of
GISTs that lack c-KIT or PDGFR mutations. More impor-
tantly, it has been shown, by a recent study that imatinib-
sensitive and -resistant GIST cells respond equally well to
a small molecular inhibitor of IGF1R, suggesting an alter-
native and/or complementary therapeutic regimen in the
clinical management of GIST, especially in tumors that
respond less favorably to imatinib-based therapy, includ-
ing pediatric cases. These findings are particularly exciting
given the number of agents targeting IGF1R that are cur-
rently being tested in clinical trials. It is feasible in the near
future to initiate clinical trials by using IGF1R-targeted
therapies for imatinib-refractory GIST patients, initially
focusing on adult and pediatric GIST patients [64].
Survival and Follow up
During the period of time that Imatinib did not been used
for GIST therapy, the 5 year survival after the surgical
resection was only 40-75%. The median survival of recur-
rent GIST after resection was 15 months in the pre-Imat-
inib era [60]. The prognosis of low risk GIST after
complete resection was excellent, but the prognosis of
high risk GIST was low and the rate of recurrence with 5
year survival ranged from 0% to 30%. However, after the
introduction of molecular targeted therapy, Imatinib,
there is a major improvement in the survival [65].
GISTs have an unpredictable behavior and a long term fol-
low up is essential for all patients, independent of their
benign or malignant characteristics. As the majority of
those GISTs tends to recur within the first 3-5 years,
intense follow up is required during this period [60].
According to the National Comprehensive Cancer Net-
work guidelines, contrast CT (Computed Tomography
Scan) of the abdomen and pelvis is recommended every
3-6 months for 3-5 years and then yearly. According to
Novitsky et al. most of the recurrence occurs during the
first 2 years after surgical resection [7]. They follow-up the
patient with physical examination every 3-4 months for 2
years, then every 6 months for the next 2 years, then
yearly. Chest X-ray and abdominal CT scan and blood test
were obtained yearly [26]. Flexible upper endoscopy is
performed at 6 months and 1-year postoperatively and
then annually for 2 years. PET (positron emission tomog-
raphy) scanning of abdomen, MR (Magnetic Resonance)
imaging, or chest CT scan is done if abnormalities are
found in any of the surveillance studies [28].
Conclusion
Gastrointestinal stromal tumors (GISTs) are the most
common mesenchymal tumors of the GI system. In most
cases, GISTs are characterized by gain-of-function muta-
tions in the KIT proto-oncogene, most commonly involv-World Journal of Surgical Oncology 2009, 7:61 http://www.wjso.com/content/7/1/61
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ing exon 11, less frequently involving exon 9, and rarely
involving exons 13 or 17 [66]. In GISTs without KIT muta-
tions, gain-of-function mutations may occur in the plate-
let-derived growth factor receptor  (PDGFR) gene,
thereby providing an alternative oncogenic mechanism
[67] GISTs' incidence, although rare, is on the rise,
because of the improved diagnostic modalities, which
offer accuracy [2]. The treatment of choice for primary
GISTs remains complete surgical resection [20]. Imatinib
mesylate is an oral tyrosine kinase inhibitor that has dra-
matically changed GIST therapy. This drug inhibits the
KIT and PDGFR tyrosine kinases as well as other mem-
bers of the type III group of tyrosine kinases [68,69]. How-
ever, after the introduction of molecular targeted therapy
with Imatinib, treatment of metastatic or recurrent GISTs
is more effective and the survival rate has improved
impressively [26]. Gastric GISTs are more common than
small bowel GISTs. Patients with malignant gastric GISTs
have a significantly better prognosis than patients with
malignant small bowel GISTs. A statistically significant
correlation was found between age and malignant poten-
tial of the GIST, by a recent study [70]. Though, the treat-
ment of primary GIST is complete gross surgical resection,
it is reasonable to consider to administer Imatinib
mesylate as a preoperative therapy in localized bulky
tumors, given its expected high response rate, as shown in
a metastatic setting [5]. Surgical resection remains the
mainstay of treatment. A formal indication to primary
Imatinib in all cases of localized unresectable GIST had
already been provided and it is consistently proposed by
all available guidelines. Nevertheless the resectability of a
tumor is hard to standardize and often considered sur-
geon dependent. It would, therefore, be rather difficult to
list criteria universally acceptable for unresectable disease
in order to provide formal indications to a preoperative
treatment [71]. Figure 1 describes GIST treatment in revi-
sion. It is well known that the major predictive factor for
tumor response to IM (Imatinib mesylate) therapy is
mutational status. Ideally, it should be taken into account
to select the patients who are more likely to benefit from
the preoperative treatment. Nevertheless it may be diffi-
cult to assess at the decision time point. Moreover, tumor
shrinkage could be observed even in cases with less favo-
rable KIT/PDGFR mutational status, with an overall
median tumor reduction of 34%. Given the limited sam-
ple size, the extent of tumor shrinkage could not be corre-
lated either to mutational status or to other clinical
features, such as tumor site, initial tumor size, imatinib
duration, and extent of pathologic response. In light of
these results the presence of a less sensitive mutation like
Exon 9 or of a wild-type KIT/PDGFR mutational status
should not be considered per se a contraindication to a
preoperative treatment, the only exception being those
point mutations with known complete resistance (i.e.
D842V in Exon 18 on PDGR gene). The only precaution
is to strictly monitor the response, by early PET/TAC re-
evaluation [72].
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MSt: search of the literature, partial English editing. ED:
editing and correction. CS: editorship of the manuscript.
PS: search of the literature. EP: editing. GL: histology con-
sulting. MSa: final editing and corrections.
References
1. Agaram NP, Besmer P, Wong CC, Guo Tianhua, Socci ND, Maki RG,
De Santis D, Brennan MF, Singer S, De Matteo RP, Antonescu CR:
Pathologic and Molecular Heterogeneity in Imatinib-Stable
or Imatinib-Responsive Gastrointestinal Stromal Tumors.
Clin Cancer Res 2007, 13(1):170-181.
Gist treatment Figure 1
Gist treatment.
 
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿



￿
￿
￿
￿
￿
￿
￿
￿


￿
￿
￿
￿
￿
￿
￿

￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿

￿
￿
￿
￿
￿
￿
￿

￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿


￿
￿
￿
￿
￿
￿
￿
￿
￿
￿

￿
￿

￿
￿
￿
￿
￿

￿
￿
￿
￿

￿
￿
￿
￿
￿
￿
￿
￿
￿
￿

￿
￿

 
!
!

￿
￿
"
￿

￿
￿
￿
￿
￿
￿
￿
￿
￿
￿
￿


￿
￿
￿
￿
￿
￿
￿
￿


	


	

World Journal of Surgical Oncology 2009, 7:61 http://www.wjso.com/content/7/1/61
Page 8 of 9
(page number not for citation purposes)
2. Joensuu H: Gastrointestinal stromal tumor (GIST).  Annals of
Oncology 2006, 17(10):280-286.
3. Mazur MT, Clark HB: Gastric stromal tumors: Reappraisal of
histogenesis.  Am J Surg Pathol 1983, 7:507-519.
4. Hirota S, Isozaki K, Moriyama Y, Hashimoto K, Nishida T, Ishiguro S,
Kawano K, Hanada M, Kurata A, Takeda M, Muhammad Tunio G,
Matsuzawa Y, Kanakura Y, Shinomura Y, Kitamura Y: Gain-of-func-
tion mutations of c-kit in human gastrointestinal stromal
tumors.  Science 1998, 279:577-580.
5. Andtbacka RH, Ng CS, Scaife CL, Cormier JN, Hunt KK, Pisters PW,
Pollock RE, Benjamin RS, Burgess MA, Chen LL, Trent J, Patel SR, Ray-
mond K, Feig BW: Surgical resection of gastrointestinal stro-
mal tumor after treatment with imatinib.  Ann Surg Oncol 2006,
14:14-24.
6. Heinrich MC, Corless CL, Duensing A, McGreevey L, Chen CJ, Joseph
N, Singer S, Griffith DJ, Haley A, Town A, Demetri GD, Fletcher CD,
Fletcher JA: PDGFRA activating mutations in gastrointestinal
stromal tumors.  Science 2003, 299:708-710.
7. Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS,
Cho MY, Jin SY, Choi JS, Kang DY: Gastrointestinal Stromal
Tumor Committee; The Korean Gastrointestinal Pathology
Study Group. Gastrointestinal Stromal Tumors in Koreans:
Incidence and the Clinical, Pathologic and Immunohisto-
chemical Findings.  J Korean Med Sci 2005, 20:977-984.
8. Tryggvason G, Gislason HG, Magnusson MK, Jónasson JG: Gastroin-
testinal stromal tumors in Iceland, 1990-2003: The Icelandic
GIST study, a population-based incidence and pathologic
risk stratification study.  Int J Cancer 2005, 117:289-293.
9. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings
RM, Hogendoorn PC: Incidence of gastrointestinal stromal
tumours is underestimated: Results of a nation-wide study.
Eur J Cancer 2005, 41:2868-2872.
10. Tran T, Davila JA, El-Serag HB: The epidemiology of malignant
gastrointestinal stromal tumors: an analysis of 1458 cases
from 1992 to 2000.  Am J Gastroenterol 2005, 100:162-168.
11. Miettinen M, Lasota J: Gastrointestinal stromal tumors - defini-
tion, clinical, histological, immunohistochemical, and molec-
ular genetic features and differential diagnosis.  Virchows Archiv
2001, 438:1-12.
12. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ,
Miettinen M, O'Leary TJ, Remotti H, Rubin BP, Shmookler B, Sobin
LH, Weiss SW: Diagnosis of gastrointestinal stromal tumors:
A consensus approach.  Hum Pathol 2002, 33:459-465.
13. Nilsson BP, Bumming P, Meis-Kindblom JM, Odén A, Dortok A, Gus-
tavsson B, Sablinska K, Kindblom LG: Gastrointestinal stromal
tumors: The incidence, prevalence, clinical course, and prog-
nostication in the preimatinib mesylate era.  Cancer 2005,
103:821-829.
14. Motegi A, Sakurai S, Nakayama H, Sano T, Oyama T, Nakajima T:
PKC theta, a novel immunohistochemical marker for gas-
trointestinal stromal tumors (GIST), especially useful for
identifying KIT-negative tumors.  Pathol Int 2005, 55:106-112.
15. Corless CL, Fletcher JA, Heinrich MC: Biology of gastrointestinal
stromal tumors.  J Clin Oncol 2004, 22:3813-3825.
16. Yan BM, Kaplan GG, Urbanski S, Nash CL, Beck PL: Epidemiology
of gastrointestinal stromal tumors in a defined Canadian
Health Region: a population-based study.  Int J Surg Pathol 2008,
16:241-250.
17. Corless CL, Schroeder A, Griffith D, Town A, McGreevey L, Harrell
P, Shiraga S, Bainbridge T, Morich J, Heinrich MC: PDGFRA Muta-
tions in Gastrointestinal Stromal Tumors: Frequency, Spec-
trum and In Vitro Sensitivity to Imatinib.  J Clin Oncol 2005,
23:5357-5364.
18. Rubin BP, Antonescu CR, Scott-Browne JP, Comstock ML, Gu Y,
Tanas MR, Ware CB, Woodell J: A knock-in mouse model of gas-
trointestinal stromal tumor harboring kit K641E.  Cancer Res
2005, 65:6631-6639.
19. Akahoshi K, Sumida Y, Matsui N, Masafumi O, Akinaga R, Kubokawa
M, Motomura Y, Honda K, Watanabe M, Nagaie T: Preoperative
diagnosis of gastrointestinal stromal tumor by endoscopic
ultrasound - guided fine needle aspiration.  World J Gastroenterol
2007, 13(14):2077-2082.
20. Jamali F, Darwiche S, El-Kinge N, Tawil A, Sowed A: Disease pro-
gression following Imatinib failure in gastrointestinal stro-
mal tumors: Role of surgical therapy.  The Ongologist 2007,
12:438-442.
21. DeMatteo RP, Lewis JJ, Leung D, Mudan SS, Woodruff JM, Brennan
MF: Two hundred gastrointestinal stromal tumors: Recur-
rence patterns and prognostic factors for survival.  Ann Surg
2000, 231:51-58.
22. Shah P, Gao F, Edmundowicz SA, Azar RR, Early DS: Predicting
Malignant Potential of Gastrointestinal Stromal Tumors
Using Endoscopic Ultrasound.  Dig Dis Sci 2009, 54:1265-1269.
23. Chak A, Canto MI, Rösch T, Dittler HJ, Hawes RH, Tio TL, Lightdale
CJ, Boyce HW, Scheiman J, Carpenter SL, Van Dam J, Kochman ML,
Sivak MV Jr: Endosonographic differentiation of benign and
malignant stromal cell tumors.  Gastrointest Endosc 1997,
45:468-473.
24. Palazzo L, Landi B, Cellier C, Cuillerier E, Roseau G, Barbier JP:
Endosonographic features predictive of benign and malig-
nant gastrointestinal stromal cell tumours.  Gut 2000,
46:88-92.
25. Kinoshita K, Isozaki K, Tsutsui S, Kitamura S, Hiraoka S, Watabe K,
Nakahara M, Nagasawa Y, Kiyohara T, Miyazaki Y, Hirota S, Nishida
T, Shinomura Y, Matsuzawa Y: Endoscopic ultrasonography-
guided fine needle aspiration biopsy in follow-up patients
with gastrointestinal stromal tumours.  Eur J Gastroenterol Hepa-
tol 2003, 15(11):1189-1193.
26. Gupta P, Tewari M, Shulka H: Gastrointestinal stromal tumor.
Surg Oncol 2008, 17(2):129-138.
27. Van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola
E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, Sil-
berman S, Nielsen OS: European Organisation for Research and
Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Safety and efficacy of imatinib (STI571) in metastatic gas-
trointestinal stromal tumours: a phase I study.  Lancet 2001,
358:1421-1423.
28. Safdar A, Sher A: Role of c-kit/SCF in cause and treatment of
gastrointestinal stromal tumors (GIST).  GENE 2007,
401:38-45.
29. Miettinen M, Sobin LH, Lasota J: Gastrointestinal stromal tumors
of the stomach: a clinicopathologic, immunohistochemical,
and molecular genetic study of 1765 cases with long-term
follow-up.  Am J Surg Pathol 2005, 29:52-68.
30. Singer S, Rubin BP, Lux ML, Chen CJ, Demetri GD, Fletcher CD,
Fletcher JA: Prognostic value of KIT mutation type, mitotic
activity, and histologic subtype in gastrointestinal stromal
tumors.  J Clin Oncol 2002, 20:3898-905.
31. Schneider-Stock R, Boltze C, Lasota J, Peters B, Corless CL, Ruem-
mele P, Terracciano L, Pross M, Insabato L, Di Vizio D, Iesalnieks I,
Dirnhofer S, Hartmann A, Heinrich M, Miettinen M, Roessner A, Tor-
nillo L: Loss of p16 protein defines high-risk patients with gas-
trointestinal stromal tumors: a tissue microarray study.  Clin
Cancer Res 2005, 11:638-645.
32. Steigen SE, Bjerkehagen B, Haugland HK, Nordrum IS, Løberg EM,
Isaksen V, Eide TJ, Nielsen TO: Diagnostic and prognostic mark-
ers for gastrointestinal stromal tumors in Norway.  Mod Pathol
2008, 21:46-53.
33. Emory TS, Sobin LH, Lukes L, Lee DH, O'Leary TJ: Prognosis of gas-
trointestinal smooth-muscle (stromal) tumors: dependence
on anatomic site.  Am J Surg Pathol 1999, 23:82-87.
34. Hornick JL, Fletcher CD: The role of KIT in the management of
patients with gastrointestinal stromal tumors.  Hum Pathol
2007, 38:679-687.
35. Taniguchi M, Nishida T, Hirota S, Isozaki K, Ito T, Nomura T, Matsuda
H, Kitamura Y: Effect of c-kit mutation on prognosis of gas-
trointestinal stromal tumors.  Cancer Res 1999, 59:4297-4300.
36. Steigen SE, Eide TJ, Wasag B, Lasota J, Miettinen M: Mutations in
gastrointestinal stromal tumors-a population-based study
from Northern Norway.  APMIS 2007, 115:289-298.
37. Verweij J, Casali PG, Zalcberg J, LeCesne A, Reichardt P, Blay JY, Issels
R, van Oosterom A, Hogendoorn PC, Van Glabbeke M, Bertulli R,
Judson I: Progression-free survival in gastrointestinal stromal
tumours with high-dose imatinib: randomised trial.  Lancet
2004, 364:1127-1134.
38. Rankin C, Von Mehren M, Blanke C: Dose effect of imatinib in
patients with metastatic GIST - Phase III Sarcoma Group
Study S0033.  Proc Am Soc Clin Oncol 2004, 23:815.
39. Parfitt J, Streutker C, Riddell R, Driman D: Gastrointestinal stro-
mal tumors: A contemporary review.  Pathology - Research and
Practice 2006, 202:837-847.World Journal of Surgical Oncology 2009, 7:61 http://www.wjso.com/content/7/1/61
Page 9 of 9
(page number not for citation purposes)
40. Blay JY, Bonvalot S, Casali P, Choi H, Debiec-Richter M, DeiTos AP,
Emile JF, Gronchi A, Hogendoorn PC, Joensuu H, Le Cesne A,
McClure J, Maurel J, Nupponen N, Ray-Coquard I, Reichardt P, Sciot
R, Stroobants S, van Glabbeke M, van Oosterom A, Demetri GD:
GIST consensus meeting panelists. Consensus meeting for
the management of gastrointestinal stromal tumors. Report
of the GIST Consensus Conference of 20-21 March 2004,
under the auspices of ESMO.  Ann Oncol 2005, 16:566-578.
41. Tamborini E, Bonadiman L, Greco A, Albertini V, Negri T, Gronchi A,
Bertulli R, Colecchia M, Casali PG, Pierotti MA, Pilotti S: A new
mutation in the KIT ATP pocket causes acquired resistance
to imatinib in a gastrointestinal stromal tumor patient.  Gas-
troenterology 2004, 127:294-299.
42. Li FP, Fletcher JA, Heinrich MC, Garber JE, Sallan SE, Curiel-Lewan-
drowski C, Duensing A, Rijn M van de, Schnipper LE, Demetri GD:
Familial gastrointestinal stromal tumor syndrome: pheno-
typic and molecular features in a kindred.  J Clin Oncol 2005,
23:2735-2743.
43. Zalcberg JR, Verweij J, Casali PG, Le Cesne A, Reichardt P, Blay JY,
Schlemmer M, Van Glabbeke M, Brown M, Judson IR: EORTC Soft
Tissue and Bone Sarcoma Group, the Italian Sarcoma
Group; Australasian Gastrointestinal Trials Group. Out-
come of patients with advanced gastrointestinal stromal
tumors (GIST) crossing over to a daily imatinib dose of 800
mg after progression on 400 mg - an international, inter-
group study of the EORTC, ISG and AGITG.  Proc Am Soc Clin
Oncol 2004, 23:815.
44. Demetri GD, van Oosterom AT, Blackstein M, Shah MH, Verweij J,
McArthur G, Judson IR, Heinrich MC, Morgan JA, Desai J, Fletcher
CD, George S, Bello CL, Huang X, Baum CM: Phase 3, multi-
center, randomized, double-blind, placebo-controlled trial of
SU11248 in patients following failure of imatinib for meta-
static GIST.  Proc Am Soc Clin Oncol 2005, 23:308s.
45. Dematteo RP, Heinrich MC, el-Rifai WM, El-Rifai WM, Demetri G:
Clinical management of gastrointestinal stromal tumors:
before and after STI-571.  Hum Pathol 2002, 33:466-477.
46. Abdulkader I, Cameselle-Teijeiro J, Forteza J: Pathological changes
related to imatinib treatment in a patient with a metastatic
gastrointestinal stromal tumour.  Histopathology 2005,
46:470-472.
47. Blay JY, Le Cesne A, Ray-Coquard I, Bui B, Duffaud F, Delbaldo C,
Adenis A, Viens P, Rios M, Bompas E, Cupissol D, Guillemet C, Ker-
brat P, Fayette J, Chabaud S, Berthaud P, Perol D: Prospective mul-
ticentric randomized phase III study of imatinib in patients
with advanced gastrointestinal stromal tumors comparing
interruption versus continuation of treatment beyond 1
year: the French Sarcoma Group.  J Clin Oncol 2007,
25:1107-1113.
48. Dogan SS, Esmaeli B: Ocular Side Effects Associated with Imat-
inib Mesylate and Perifosine for Gastrointestinal Stromal
Tumor.  Hematol Oncol Clin North Am 2009, 23(1):109-114.
49. Cerchione C, Fabbricini R, Pane F, Luciano L: Vitiligo-like lesions in
an adult patient treated with Imatinib Mesylate.  Leukemia
Research 2009, 33:e104-105.
50. Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P,
Schöffski P: The clinical implications of sunitinib-induced
hypothyroidism: a prospective evaluation.  British Journal of Can-
cer 2008, 99:448-454.
51. Alexandrescu DT, Dasanu CA, Farzanmehr H, Kauffman L: Persist-
ent cutaneous hyperpigmentation after tyrosine kinase inhi-
bition with imatinib for GIST.  Dermatology Online Journal 2008,
4(7):7.
52. Yokoyama A, Dairaku N, Kusano M, Koshita S, Shimada N, Yamagiwa
T, Kojima Y, Ojima T, Ikeya S, Nakayama H, Sugai Y, Hiwatashi N,
Asano S: Two cases of primary unresectable and/or recurrent
gastrointestinal stromal tumors of small intestine present-
ing hemoperitoneum caused by administration of imatinib
mesylate.  Nippon Shokakibyo Gakkai Zasshi 2008, 105:1619-1626.
53. Chintalgattu V, Patel SS, Khakoo AY: Cardiovascular Effects of
Tyrosine Kinase Inhibitors Used for Gastrointestinal Stro-
mal Tumors.  Hematol Oncol Clin North Am 2009, 3(1):97-107.
54. Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ: Serosal
inflammation (pleural and pericardial effusions) related to
tyrosine kinase inhibitors.  Targ Oncol 2009, 4:99-105.
55. Demetri GD, von Mehren M, Blanke CD, Abbeele AD Van den, Eisen-
berg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M,
Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng
B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CD, Joensuu H: Effi-
cacy and safety of imatinib mesylate in advanced gastrointes-
tinal stromal tumors.  N Engl J Med 2002, 347:472-480.
56. Loughrey MB, Mitchell C, Mann M, Michael GB, Waring PM: Gas-
trointestinal stromal tumor treated with neoadjuvant imat-
inib.  J Clin Pathol 2005, 58:779-781.
57. Pauwels P, Debiec-Rychter M, Stul M, De Wever I, Van Oosterom
AT, Sciot R: Changing phenotype of gastrointestinal stromal
tumours under imatinib mesylate treatment: potential diag-
nostic pitfall.  Histopathology 2005, 47:41-47.
58. Basu S, Balaji S, Bennett D, Davies N: Gastrointestinal stromal
tumors (GIST) and laparoscopic resection.  Surg Endosc 2007,
21:1685-1689.
59. Efremidou E, Liratzopoulos N, Papageorgiou M, Romanidis K: Perfo-
rated GIST of the small intestine as a rare cause of acute
abdomen: Surgical treatment and adjuvant therapy. Case
report.  J Gastrointestin Liver Dis 2006, 15(3):297-299.
60. Tsukuda K, Hirai R, Miyake T, Takagi S, Ikeda E, Kunitomo T, Tsuji H:
The outcome of gastrointestinal stromal tumors (GISTs)
after a surgical resection in our institute.  Surgery today 2007,
37:953-957.
61. Rossi F, Ehlers I, Agosti V, Socci ND, Viale A, Sommer G, Yozgat Y,
Manova K, Antonescu CR, Besmer P: Oncogenic Kit signaling and
therapeutic intervention in a mouse model of gastrointesti-
nal tumor.  Proc Natl Acad Sci USA 2006, 103:12843-12848.
62. Sommer G, Agosti V, Ehlers I, Rossi F, Corbacioglu S, Farkas J, Moore
M, Manova K, Antonescu CR, Besmer P: Gastrointestinal stromal
tumors in a mouse model by target mutation of the Kit
receptor tyrosine kinase.  Proc Natl Acad Sci USA 2003,
100:6706-6711.
63. Bauer S, Yu LK, Demetri GD, Fletcher JA: Heat shock protein 90
inhibition in imatinib-resistant gastrointestinal tumor.  Can-
cer Res 2006, 66:9153-9161.
64. Tarn C, Rink L, Merkel E, Flieder D, Pathak H, Koumbi D, Testa JR,
Eisenberg B, von Mehren MGodwin AK: Insulin-like growth factor
1 receptor is a potential therapeutic target for gastrointesti-
nal stromal tumors.  PNAS 2008, 105:8387-8392.
65. Ponsaing L, Hansen MB: Therapeutic procedures fir submucosal
tumors in the gastrointestinal tract.  World J Gastroenterol 2007,
13(24):3316-22.
66. Kim TW, Lee H, Kang YK, Choe MS, Ryu MH, Chang HM, Kim JS,
Yook JH, Kim BS, Lee JS: Prognostic significance of c-kit muta-
tion in localized gastrointestinal stromal tumors.  Clin Cancer
Res 2004, 10:3076-3081.
67. Debiec-Rychter M, Wasag B, Stul M, De Wever I, Van Oosterom A,
Hagemeijer A, Sciot R: Gastrointestinal stromal tumours
(GISTs) negative for KIT (CD117 antigen) immunoreactiv-
ity.  J Pathol 2004, 202:430-438.
68. Buchdunger E, Cioffi CL, Law N, Stover D, Ohno-Jones S, Druker BJ,
Lydon NB: Abl protein-tyrosine kinase inhibitor STI571 inhib-
its in vitro signal transduction mediated by c-kit and platelet
derived growth factor receptors.  J Pharmacol Exp Ther 2000,
295:139-145.
69. Kim T, Ryu MH, Lee H, Sym SJ, Lee JL, Chang HM, Park YS, Lee KH,
Kang WK, Shin DB, Bang YJ, Lee JS, Kang YK: Kinase Mutations
and Efficacy of Imatinib in Korean Patients with Advanced
Gastrointestinal Stromal Tumors.  The Oncologist 2009,
14:540-547.
70. Rabin I, Chikman B, Lavy R, Sandbank J, Maklakovsky M, Gold-Deutch
R, Halpren Z, Wassermann I, Halevy A: Gastrointestinal Stromal
Tumors: A 19 Year Experience.  IMAJ 2009, 11:98-102.
71. Fiore M, Palassini E, Fumagalli E, Pilotti S, Tamborini E, Stacchiotti S,
Pennacchioli E, Casali PG, Gronchi A: Preoperative imatinib
mesylate for unresectable or locally advanced primary gas-
trointestinal stromal tumors (GIST).  EJSO 2009, 35:739-745.
72. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA,
Demetri GD, Abbeele AD Van den: CT and PET: early indicators
of response to imatinib mesylate in patients with gastroin-
testinal stromal tumor.  AJR 2007, 189:W324-330.